Satya Pharma Innovations Private Limited

Satya is a DDR focused drug discovery company, and has pioneered RAD51 inhibition as a potentially foundational therapeutic for high replication stress solid tumors. In addition to first- and best-in-class DDR programs, Satya additionally focuses on targeted pan-cancer therapeutics that can address a wide variety of tumors Satyas world-class scientific team is driven by a commitment to excellence, and has experience of working on over 75 targets that have led to over 15 global clinical programs, including one FDA-approved oncology drug

Oncology,drug discovery,cell & molecular biology,medicinal chemistry,small-molecules,nces,synthetic lethality,ddr pathway,oncogenes,kras,egfr,and pan-cancer therapeutics

Satya pharma innovations private limited operates in the Biotechnology research industry.

Satya pharma innovations private limited's revenue is 11m - 100m

Satya pharma innovations private limited has 11 - 50 employees.